Navigation Links
Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income
Date:9/24/2009

,392,639 $1,337,682 Short-term bank loans 1,399,075 1,393,345 VAT taxes payable 458,930 277,090 Income taxes payable 490,514 341,214 Other taxes payable 11,890 39,939 Dividends payable 325,417 378,545 Other current liabilities 307,934 142,733 Total current liabilities 4,386,399 3,910,548 Total liabilities 4,386,399 3,910,548 Stockholders' equity: Common stock, $0.001 par value, 50,000,000 shares authorized, 17,908,912 and 14,738,450 shares issued and outstanding at June 30, 2009 and 2008, respectively 17,909 14,739 Series A convertible preferred stock, $0.001 par value, 7,146,500 and 9,384,375 shares issued and outstanding at June 30, 2009 and 2008, respectively 7,147 9,384 Additional paid-in capital 19,694,514 18,002,439 Statutory reserve 2,299,807 1,380,806 Treasury stock (111,587) -- Retained earnings 16,486,775 10,963,131 Accumulated other comprehensive income 2,551,380 2,477,874 Total stockholders' equity 40,945,945 32,848,373 Total liabilities and stockholders' equity $45,322,344 $36,758,921

Consolidated Statements of Operations and Comprehensive Income

                                                   For the Years Ended June 30,
                                                        2009  
'/>"/>
SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Tianyin Pharmaceutical, Inc. to Host 2008 Second Quarter Earnings Conference Call on Thursday, February 14, 2008 at 4:15 p.m. EST
2. Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results
3. Tianyin Pharmaceutical Appoints Three New Independent Board Members
4. Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets
5. Tianyin Pharmaceutical to Present at the Brean Murray All-Cap All-China Conference in New York City on May 20, 2008 at 10:15 a.m. EDT
6. Tianyin Pharmaceutical Co., Inc. to Present at Rodman & Renshaw Annual Global Investment Conference in New York City on November 11, 2008 at 12:00 p.m. EST
7. Tianyin Pharmaceutical Co., Inc. Announces First Quarter 2009 Financial Results
8. Tianyin Pharmaceutical Co., Inc. Implements New Sales and Marketing Strategy to Drive Revenue Growth
9. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Wednesday, February 18, 2009 at 8:45 a.m. EST
10. Tianyin Pharmaceutical Co., Inc. Adopts New Sales Strategy for Azithromycin Dispersible Tablets
11. Tianyin Pharmaceutical Co., Inc. Announces Cash Dividend to Common Stockholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... ... 03, 2015 , ... The latest addition to the Mettler-Toledo PCE ... automatically. Companies in the pharmaceutical and healthcare industry can use the LSS to print ... The Label Serialization Station can be fully integrated into the production line and is ...
(Date:9/3/2015)... ... September 03, 2015 , ... UCLA ... months ago. Conventional treatment and therapy were not working so Zach decided to ... Dr. McKenna treated Zack with precisely guided injections of bone marrow aspirate concentrate ...
(Date:9/3/2015)... , Sept. 3, 2015  Guardant Health®, the ... abstracts highlighting the performance and clinical utility of ... for oral and poster presentations at the International ... World Conference on Lung Cancer. These abstracts were ... of California, Davis; the University of Chicago; Sarah ...
(Date:9/3/2015)... , Sept. 3, 2015  Vermillion, Inc. (NASDAQ: ... gynecologic disease, today announced that Herbert Fritsche , ... ASPiRA LABS, is the recipient of the 2015 Abbott ... Biomarkers (ISOBM) for outstanding contributions to the field of ... award on October 5 th in Zakopane, ...
Breaking Biology Technology:Print and Verify Labels On The Production Line With New Label Serialization Stations 2Print and Verify Labels On The Production Line With New Label Serialization Stations 3UCLA Wide Receiver and Canadian Decathlon Standout Zack Bornstein Bounces Back After Stem Cell Therapy at Riordan-McKenna Institute 2UCLA Wide Receiver and Canadian Decathlon Standout Zack Bornstein Bounces Back After Stem Cell Therapy at Riordan-McKenna Institute 3Leading Cancer Centers to Present Clinical Utility Data For Guardant360 At IASLC's 16th World Conference on Lung Cancer in Denver Sept. 6-9 2Leading Cancer Centers to Present Clinical Utility Data For Guardant360 At IASLC's 16th World Conference on Lung Cancer in Denver Sept. 6-9 3Leading Cancer Centers to Present Clinical Utility Data For Guardant360 At IASLC's 16th World Conference on Lung Cancer in Denver Sept. 6-9 4Vermillion Announces Dr. Herbert Fritsche as Recipient of the 2015 Abbott Award from the International Society of Oncology and Biomarkers 2
... Newly formed Advisory Board to advise on cancer screening ... mitochondrial DNA-based ... Inc. (OTC,Bulletin Board: TBIO) today announced that it has ... the latest developments and,scientific opportunities in cancer detection screening ...
... ... Use, LA JOLLA, Calif., Jan. 17 Stemagen, a privately ... in the world to create, and meticulously document, a cloned human,embryo ... Wood, M.D., Ph.D., a co-author of the,publication and a donor of ...
... Trial will also Support a Marketing Authorization Application in the ... ... Agennix Incorporated announced today,that the U.S. Food and Drug Administration ... evaluating its lead molecule,talactoferrin alfa, in combination with chemotherapy as first-line,treatment ...
Cached Biology Technology:Transgenomic, Inc. Forms Scientific Advisory Board 2Transgenomic, Inc. Forms Scientific Advisory Board 3Stemagen First to Create Cloned Human Embryos From Adult Cells 2Stemagen First to Create Cloned Human Embryos From Adult Cells 3Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 2Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 3Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 4Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 5
(Date:9/2/2015)... Sept. 2, 2015 About hand geometry biometrics ... banks, government organizations, telecommunication and hospitals as well as ... badges, and numeric keypads are used to prevent unauthorised ... palm and fingers of an individual, width of the ... with infrared light and reflectors can be used for ...
(Date:9/2/2015)... , Sept. 2, 2015 Security of ... for enterprises, banks, government organizations, telecommunications, hospitals, as ... keypads were previously being used to prevent unauthorised ... two-factor authentication, wherein individuals could gain access to ... components, such as hardware devices and numeric codes. ...
(Date:9/2/2015)... , September 2, 2015 ... security purpose implied in a system which uses ... voice, signature, iris, vein, DNA and finger print. ... forced to develop such system which provides high ... password, PIN, Patterns and tokens are vulnerable to ...
Breaking Biology News(10 mins):Global Hand Geometry Biometrics Market 2015-2019 2Global Hand Geometry Biometrics Market 2015-2019 3Global Biometrics Spending Market in the Government Sector 2015-2019 2Global Biometrics Spending Market in the Government Sector 2015-2019 3Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 2Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 3Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 4
... the McKnight Brain Institute of the University of Florida ... other diseases by plundering the secrets of regeneration from ... newts, starfish and flatworms. , Fueled by about $6 ... funds, "The Regeneration Project" will connect scientists who work ...
... how different species use common genes to control their ... to accommodate their own features. The findings, which were ... Small’s laboratories in NYU’s Center for Developmental Genetics, offer ... species. The study is published in the latest issue ...
... medical practice that an antiretroviral drug widely used to treat ... own in patients co-infected with HIV. Their findings demonstrate ... drugs used to treat the AIDS virus. , "Our results ... has been shown to be active against HIV - it ...
Cached Biology News:Research project tackles 'regeneration' gap 2Research project tackles 'regeneration' gap 3NYU scientists identify how development of different species uses same genes with distinct features 2Widely used hepatitis B drug spurs HIV drug resistance 2Widely used hepatitis B drug spurs HIV drug resistance 3
Human peripheral blood PBMCs, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood PBMC and T Cells...
Umbilical cord blood CD14+ Monocytes, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Human peripheral blood CD8+ T cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood PBMC and T Cells...
Human peripheral blood CD56+ NK cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Biology Products: